低FODMAP饮食对患有刺激性肠综合征的患者的影响
Amani A Alrasheedi1, Esra A Jahlan2, Marwan A Bakarman3
1Department of Food and Nutrition, Faculty of Human Sciences and Design, King Abdulaziz University, Jeddah, Saudi Arabia. aalrasheedi@kau.edu.sa.
Scientific reports
|May 11, 2025
概括
低 Fermentable Oligosaccharides,Disaccharides,Monosaccharides,Polyols (FODMAP) 的饮食改善了吉达成年人的刺激性肠综合征 (IBS) 症状. 由于潜在的体重和营养素变化,专业指导至关重要.
科学领域:
- 胃肠病学 胃肠病学
- 饮食科学 饮食科学
- 临床营养学 临床营养学
背景情况:
- 刺激性肠综合征 (IBS) 是一种慢性胃肠疾病,导致腹痛和改变肠道习惯.
- 饮食干预是控制IBS症状的关键.
- 低发酵性寡糖,脱糖,单糖,多醇 (FODMAP) 饮食是IBS管理的公认方法.
研究的目的:
- 为了评估低FODMAP饮食干预措施对成年IBS患者在沙特阿拉伯吉达市的有效性.
- 评估患有轻度和重度刺激性肠综合征的患者的症状变化.
- 分析低FODMAP饮食对IBS症状严重程度和饮食习惯的影响.
主要方法:
- 在45名IBS成人患者中实施了低FODMAP饮食干预措施.
- 使用验证的IBS-SSS问卷来测量症状严重程度.
- 人类测量测量和饮食数据是使用验证的问卷收集的.
主要成果:
- 低FODMAP饮食干预导致刺激性肠综合征症状显著改善.
- 干预后,从中度/重度症状发生了显著的转变,主要是中度/轻度症状.
- 这项干预鼓励参与者养成更健康的饮食习惯.
结论:
- 低FODMAP饮食在改善成人群体内IBS症状方面是有效的.
- 由于饮食的限制性质,潜在的体重变化和营养缺乏,建议仔细监测.
- 专业指导对于实施低FODMAP饮食干预措施至关重要.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
253
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
253
Irritable Bowel Syndrome III: Medical and Nursing Management
123
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
123
Drugs for Treatment of Diarrhea-Predominant IBS
126
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
126
Irritable Bowel Syndrome I: Introduction
209
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
209
Drugs for Treatment of Constipation-Predominant IBS
117
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
117
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
99
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
99


